Genentech, MedImmune settle over Cabilly patent

On June 11, Genentech announced it had settled with MedImmune concerning the dispute over the Cabilly patent.

Marilyn Chase of the WSJ reported: The settlement dismisses MedImmune's challenge of the patent, under which it pays royalties to Genentech on sales of its product Synagis, which is used to prevent respiratory infection in infants. The settlement resolves that dispute related to Synagis, as well as a related experimental product on which it is seeking regulatory approval.


Forbes has an article titled Genentech settles dispute with MedImmune related to Cabilly patent

Note previous posts on IPBiz, which included discussion of the re-examination:

http://ipbiz.blogspot.com/2007/02/uspto-gives-final-rejection-in-re-exam.html

http://ipbiz.blogspot.com/2007/01/value-of-genentechs-cabilly-patent.html